Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EPS (Weighted Average and Diluted) (2016 - 2025)

IGC Pharma (IGC) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$0.02 as the latest value for Q3 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed 0.0% to -$0.02 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$0.07 through Sep 2025, up 61.11% year-over-year, with the annual reading at -$0.09 for FY2025, 59.09% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.02 at IGC Pharma, roughly flat from -$0.02 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.01 in Q1 2025, with the low at -$0.09 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.03, with a median of -$0.02 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 77.78% in 2024, then changed 0.0% in 2025.
  • Over 3 years, EPS (Weighted Average and Diluted) stood at -$0.09 in 2023, then soared by 77.78% to -$0.02 in 2024, then changed by 0.0% to -$0.02 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.02, -$0.02, and -$0.01 for Q3 2025, Q2 2025, and Q1 2025 respectively.